Doraiswamy P M, Bieber F, Kaiser L, Connors K, Krishnan K R, Reuning-Scherer J, Gulanski B
Department of Psychiatry, Duke University Medical Center, Durham, NC 27710, USA.
Psychopharmacol Bull. 1997;33(1):123-8.
The cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog) is designed specifically to assess memory, language, and praxis dysfunctions characteristic of Alzheimer's disease (AD). In this report, we use data from 1,648 AD participants in two identical 26-week multicenter drug trials to derive clinical trial population-based norms for ADAS-Cog subtest scores. All 11 ADAS-Cog item scores were sensitive to differences in dementia severity judged either by baseline Mini-Mental State Exam (MMSE) scores or by Global Deterioration Scale (GDS) stage of dementia. Using ADAS-Cog subtest scores alone, 85 percent of GDS 4 subjects and 69 percent of GDS 5 subjects could be classified correctly. In a stepwise discriminant analysis, orientation was the item with the greatest discriminatory power between subjects with GDS 4 and GDS 5 stages of dementia. ADAS-Cog subtest scores also varied by age, gender, educational level, and concurrent use of anti-inflammatory drugs or estrogen (in women). Such normative data may facilitate the selection of appropriate outcome measures to investigate differential treatment effects on specific cognitive domains or in specific AD subpopulations.
阿尔茨海默病评估量表认知分量表（ADAS-Cog）专门用于评估阿尔茨海默病（AD）特有的记忆、语言和运用功能障碍。在本报告中，我们使用了两项为期26周的多中心药物试验中1648名AD参与者的数据，以得出基于临床试验人群的ADAS-Cog子测试分数的规范值。所有11项ADAS-Cog项目分数对通过基线简易精神状态检查表（MMSE）分数或痴呆症总体衰退量表（GDS）阶段判断的痴呆症严重程度差异均敏感。仅使用ADAS-Cog子测试分数，85%的GDS 4期受试者和69%的GDS 5期受试者能够被正确分类。在逐步判别分析中，定向是在痴呆症GDS 4期和GDS 5期受试者之间具有最大判别力的项目。ADAS-Cog子测试分数也因年龄、性别、教育水平以及是否同时使用抗炎药物或雌激素（女性）而有所不同。这些规范数据可能有助于选择合适的结局指标，以研究对特定认知领域或特定AD亚组的不同治疗效果。
